Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies

Dawn M.R. Davis; Aaron M. Drucker; Ali Alikhan; Lionel Bercovitch; David E. Cohen; Jennifer M. Darr; Lawrence F. Eichenfield; Lindsy Frazer-Green; Amy S. Paller; Kathryn Schwarzenberger; Jonathan I. Silverberg; Anne Marie Singh; Peggy A. Wu; Robert Sidbury

doi:10.1016/j.jaad.2023.08.103

Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies

Dawn M.R. Davis, Aaron M. Drucker, Ali Alikhan, Lionel Bercovitch, David E. Cohen, Jennifer M. Darr, Lawrence F. Eichenfield, Lindsy Frazer-Green, Amy S. Paller, Kathryn Schwarzenberger, Jonathan I. Silverberg, Anne Marie Singh, Peggy A. Wu, Robert Sidbury

Dermatology

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The summarized guidelines update the 2014 recommendations for the management of AD with phototherapy and systemic therapies. Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading recommendations. Results: The workgroup developed 11 recommendations on the management of AD in adults with phototherapy and systemic therapies, including biologics, oral Janus Kinase inhibitors, and other immunomodulatory medications. Conclusions: The evidence supported strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib and conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids.

Original language	English (US)
Pages (from-to)	342-345
Number of pages	4
Journal	Journal of the American Academy of Dermatology
Volume	90
Issue number	2
DOIs	https://doi.org/10.1016/j.jaad.2023.08.103
State	Published - Feb 2024

Keywords

JAK inhibitor
atopic dermatitis
azathioprine
biologic
cyclosporine
dupilumab
eczema
methotrexate
phototherapy

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2023.08.103

Cite this

Davis, D. M. R., Drucker, A. M., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., Silverberg, J. I., Singh, A. M., Wu, P. A., & Sidbury, R. (2024). Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology, 90(2), 342-345. https://doi.org/10.1016/j.jaad.2023.08.103

Davis, DMR, Drucker, AM, Alikhan, A, Bercovitch, L, Cohen, DE, Darr, JM, Eichenfield, LF, Frazer-Green, L, Paller, AS, Schwarzenberger, K, Silverberg, JI, Singh, AM, Wu, PA & Sidbury, R 2024, 'Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies', Journal of the American Academy of Dermatology, vol. 90, no. 2, pp. 342-345. https://doi.org/10.1016/j.jaad.2023.08.103

@article{243832316300492cbcb9b47ac2972e45,

title = "Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies",

abstract = "Background: The summarized guidelines update the 2014 recommendations for the management of AD with phototherapy and systemic therapies. Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading recommendations. Results: The workgroup developed 11 recommendations on the management of AD in adults with phototherapy and systemic therapies, including biologics, oral Janus Kinase inhibitors, and other immunomodulatory medications. Conclusions: The evidence supported strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib and conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids.",

keywords = "JAK inhibitor, atopic dermatitis, azathioprine, biologic, cyclosporine, dupilumab, eczema, methotrexate, phototherapy",

author = "Davis, {Dawn M.R.} and Drucker, {Aaron M.} and Ali Alikhan and Lionel Bercovitch and Cohen, {David E.} and Darr, {Jennifer M.} and Eichenfield, {Lawrence F.} and Lindsy Frazer-Green and Paller, {Amy S.} and Kathryn Schwarzenberger and Silverberg, {Jonathan I.} and Singh, {Anne Marie} and Wu, {Peggy A.} and Robert Sidbury",

note = "Publisher Copyright: {\textcopyright} 2023 American Academy of Dermatology, Inc.",

year = "2024",

month = feb,

doi = "10.1016/j.jaad.2023.08.103",

language = "English (US)",

volume = "90",

pages = "342--345",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Executive summary

T2 - Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies

AU - Davis, Dawn M.R.

AU - Drucker, Aaron M.

AU - Alikhan, Ali

AU - Bercovitch, Lionel

AU - Cohen, David E.

AU - Darr, Jennifer M.

AU - Eichenfield, Lawrence F.

AU - Frazer-Green, Lindsy

AU - Paller, Amy S.

AU - Schwarzenberger, Kathryn

AU - Silverberg, Jonathan I.

AU - Singh, Anne Marie

AU - Wu, Peggy A.

AU - Sidbury, Robert

PY - 2024/2

Y1 - 2024/2

N2 - Background: The summarized guidelines update the 2014 recommendations for the management of AD with phototherapy and systemic therapies. Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading recommendations. Results: The workgroup developed 11 recommendations on the management of AD in adults with phototherapy and systemic therapies, including biologics, oral Janus Kinase inhibitors, and other immunomodulatory medications. Conclusions: The evidence supported strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib and conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids.

AB - Background: The summarized guidelines update the 2014 recommendations for the management of AD with phototherapy and systemic therapies. Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading recommendations. Results: The workgroup developed 11 recommendations on the management of AD in adults with phototherapy and systemic therapies, including biologics, oral Janus Kinase inhibitors, and other immunomodulatory medications. Conclusions: The evidence supported strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib and conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids.

KW - JAK inhibitor

KW - atopic dermatitis

KW - azathioprine

KW - biologic

KW - cyclosporine

KW - dupilumab

KW - eczema

KW - methotrexate

KW - phototherapy

UR - http://www.scopus.com/inward/record.url?scp=85177784295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85177784295&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2023.08.103

DO - 10.1016/j.jaad.2023.08.103

M3 - Article

C2 - 37943240

AN - SCOPUS:85177784295

SN - 0190-9622

VL - 90

SP - 342

EP - 345

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 2

ER -

Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this